-transparent.png){kind=logo}
MCA serum levels were determined in 27 healthy subjects, 136 with benign pathology (42 breast) and in 289 patients with cancer (247 active). The last group includes 223 patients with breast cancer (96 without metastases, 89 with metastases and 38 no-evidence of disease). CEA and CA15-3 serum levels were determined in all the patients with breast diseases. The mean levels of MCA were 4.7 + 2.4 U/ml in the control group, considering less than 11 U/ml as normal. MCA values were abnormal in 15.4% of patients with benign pathology, mainly in those with liver cirrhosis (8/20) and lung diseases (4/20). In the majority of these cases, the rise was only moderate, lower than 15 U/ml in 97.5% of patients. In malignant diseases, important increments were found in breast cancer (19.8% Mo, 77.5% M1) and ovarian cancer stages III-IV (44.4%). When we compared MCA serum levels with CA15-3 and CEA in breast pathology, a similar specificity was observed: 92.3%, 92.3% and 100% in cases with benign pathology and 92.1%, 94.7%, and 97.4% in NED patients, respectively. MCA and CA15-3 sensitivity was similar in breast cancer without metastases (19.8%) and lower for CEA (16.7%). In patients with breast cancer without metastases, we found a relation between positivity of these tumor markers and prognostic factors (tumor size, nodal involvement). The disease free interval in patients with locoregional breast cancer was shorter in cases with abnormal presurgical levels of some of the tumor markers, but only the difference from MCA was significant (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
September 1999,
The Kaohsiung journal of medical sciences,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
December 1995,
Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
August 2020,
Molecular and clinical oncology,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
October 2009,
Medicina oral, patologia oral y cirugia bucal,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
January 1998,
Tumori,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
January 2016,
Journal of Cancer,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
January 1993,
Cancer detection and prevention,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
July 1995,
Rinsho byori. The Japanese journal of clinical pathology,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
January 2019,
Medical journal of the Islamic Republic of Iran,
R Molina, and
X Filella, and
P Mengual, and
M Prats, and
G Zanon, and
M Daniels, and
A M Ballesta
August 2011,
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
